Omeros Corporation (OMER) Earns Buy Rating from Cantor Fitzgerald
Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Monday. They currently have a $21.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 176.32% from the stock’s current price.
Several other equities research analysts have also commented on the company. Zacks Investment Research lowered Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, October 12th. FBR & Co restated an “outperform” rating and set a $38.00 target price on shares of Omeros Corporation in a research report on Wednesday, June 29th. Maxim Group cut their target price on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Wedbush restated an “outperform” rating and set a $56.00 target price (down previously from $62.00) on shares of Omeros Corporation in a research report on Thursday, August 11th. Finally, WBB Securities reaffirmed a “buy” rating and set a $75.00 price target on shares of Omeros Corporation in a research note on Monday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $32.45.
Omeros Corporation (NASDAQ:OMER) traded up 3.54% on Monday, reaching $7.60. The company’s stock had a trading volume of 3,939,905 shares. The company’s market cap is $298.63 million. The firm’s 50-day moving average price is $10.60 and its 200 day moving average price is $11.73. Omeros Corporation has a 52-week low of $7.26 and a 52-week high of $16.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/omeros-corporation-omer-earns-buy-rating-from-cantor-fitzgerald.html
Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.18. The business had revenue of $10 million for the quarter, compared to the consensus estimate of $9.80 million. During the same quarter in the previous year, the company earned ($0.44) EPS. The firm’s revenue for the quarter was up 212.5% on a year-over-year basis. Equities analysts anticipate that Omeros Corporation will post ($1.55) EPS for the current fiscal year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the sale, the vice president now directly owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the completion of the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Omeros Corporation during the second quarter valued at approximately $105,000. Bourgeon Capital Management LLC bought a new stake in shares of Omeros Corporation during the second quarter valued at approximately $158,000. BlackRock Advisors LLC increased its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the period. BlackRock Group LTD increased its stake in shares of Omeros Corporation by 64.4% in the first quarter. BlackRock Group LTD now owns 12,080 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 4,734 shares during the period. Finally, Mesirow Financial Investment Management Equity Management bought a new stake in shares of Omeros Corporation during the second quarter valued at approximately $244,000. 48.04% of the stock is owned by hedge funds and other institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.